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ABSTRACT
Equilibrative nucleoside transporters (ENTs), which
facilitate cross-membrane transport of nucleosides and
nucleoside-derived drugs, play an important role in the
salvage pathways of nucleotide synthesis, cancer
chemotherapy, and treatment for virus infections.
Functional characterization of ENTs at the molecular
level remains technically challenging and hence scant.
In this study, we report successful puriﬁcation and bio-
chemical characterization of human equilibrative nucle-
oside transporter 1 (hENT1) in vitro. The HEK293F-
derived, recombinant hENT1 is homogenous and func-
tionally active in proteoliposome-based counter ﬂow
assays. hENT1 transports the substrate adenosine with
a Km of 215 ± 34 µmol/L and a Vmax of 578 ± 23.4 nmol
mg−1 min−1. Adenosine uptake by hENT1 is competi-
tively inhibited by nitrobenzylmercaptopurine ribonu-
cleoside (NBMPR), nucleosides, deoxynucleosides, and
nucleoside-derived anti-cancer and anti-viral drugs.
Binding of hENT1 to adenosine, deoxyadenosine, and
adenine by isothermal titration calorimetry is in general
agreement with results of the competitive inhibition
assays. These results validate hENT1 as a bona ﬁde
target for potential drug target and serve as a useful
basis for future biophysical and structural studies.
KEYWORDS hENT1, nucleoside, functional
characterization, transport, counter ﬂow
INTRODUCTION
Uptake of nucleoside is required for DNA and RNA synthesis
and plays a key role in signaling, exempliﬁed by adenosine
interaction with the cell surface P1 purinergic receptors,
which elicits a range of physiological responses including
coronary vasodilation, renal vasoconstriction, and platelet
aggregation (Kong et al., 2004; Jaakola et al., 2008; Young
et al., 2013; Wall and Richardson, 2015). The same mech-
anism that mediates nucleoside uptake is also responsible
for the transport of nucleoside-derived drugs, which are
widely used to treat virus infections and cancer (King et al.,
2006; Jordheim and Dumontet, 2007; Jordheim et al., 2013).
In mammalian cells, nucleosides are transported by two
different nucleoside transporters: the concentrative sodium-
dependent nucleoside transporter (CNT), which corresponds
to the SLC28 family, and the equilibrative nucleoside trans-
porter (ENT), which pertains to the SLC29 family (Baldwin
et al., 2004; Gray et al., 2004; Young et al., 2013; Young,
2016).
The ENT family, identiﬁed in many higher eukaryotes,
contain four members in human, namely hENT1, hENT2,
hENT3 and hENT4 (Grifﬁths et al., 1997a; Grifﬁths et al.,
1997b; Hyde et al., 2001; Baldwin et al., 2004; Barnes et al.,
2006; Govindarajan et al., 2009; Boswell-Casteel and Hays,
2016; Young, 2016). hENT1 shares 47, 33, and 24 percent
sequence identity with hENT2, hENT3, and hENT4,
respectively. All ENTs are thought to share the same general
topology and structure, which consist of 11 transmembrane
segments (TMs), a cytoplasmic N-terminus and an extra-
cellular C-terminus, a large extracellular loop between TM1
and TM2, and a large cytoplasmic loop between TM6 and
TM7 (Sundaram et al., 2001; Valdes et al., 2009; Valdes
et al., 2014).
Expression of ENTs is a predictive biomarker for drug
efﬁcacy in cancer treatment (Giovannetti et al., 2006;
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Borbath et al., 2012; Nordh et al., 2014; Pastor-Anglada and
Perez-Torras, 2015; Svrcek et al., 2015). However, the cur-
rent level of knowledge on the structure and function of ENTs
is vastly inadequate, given their general importance in drug
development. There is no detailed structural information on
any member of the ENT family. Rigorous effort aimed at
structural elucidation of ENTs has been hampered by the
technical challenge of recombinant expression in functional
form. At present, the only piece of relevant structural infor-
mation is the crystal structure of CNT transporters (CNTs)
from Gram-negative bacterium Vibrio cholera (vcCNT)
(Johnson et al., 2012; Johnson et al., 2014). vcCNT shares
14.9 percent sequence identity with hENT1. Although this
information facilitates our understanding of the molecular
mechanism for nucleoside transport and recognition of the
CNTs, it provides no assistance to mechanistic under-
standing of the ENTs. Therefore, hENT1 represents a highly
prioritized target for biochemical and structural investigation.
In this study, we report successful overexpression and
puriﬁcation of hENT1 in human HEK293F cells and char-
acterization of its biochemical and biophysical properties.
We reconstituted a substrate transport assay using hENT1-
incorporated proteoliposomes for in vitro functional studies.
We report the kinetics and transport activities of hENT1 for a
number of nucleosides and nucleoside-derived drugs in
proteoliposome-based counter ﬂow assays. This information
constitutes an important basis for mechanistic understanding
of hENT1 as well as for future structural studies.
RESULTS
Expression and puriﬁcation of hENT1
The predicted secondary structure of hENT1 (residues 1–
456) conforms to that of the SLC29 family, with 11 TMs, an
amino-terminus in the cytoplasm, and a carboxyl-terminus in
the extracellular side (Fig. 1A). hENT1 contains two exten-
ded loops: one between TM1 and TM2, and the other
between TM6 and TM7 (Fig. 1A). A known N-linked glyco-
sylation site on Asn48 is located in loop 1 (Sundaram et al.,
2001) (Fig. 1A). During intense effort in the past several
years (Li et al., 2009; Reyes et al., 2010; Reyes et al., 2011;
Rehan et al., 2015; Rehan and Jaakola, 2015), none of the
four hENTs has been puriﬁed to homogeneity and conse-
quently no puriﬁed hENT has been biochemically charac-
terized. To obtain recombinant, homogeneous hENT1 for
functional studies, we explored different expression systems
—bacterial, baculovirus-infected insect cells, and mam-
malian cell tissue culture—in combination with exhaustive
protein engineering endeavor. After years of trials, we
focused on the mammalian expression system.
Finally, a full-length hENT1 variant (residues 1-456,
N48Q) with the glycosylation site eliminated was cloned into
the pCAG plasmid for transient expression in human
HEK293F cells. The choice of detergent proved to be vital for
hENT1 extraction and puriﬁcation. Following an exhaustive
screening of detergents including DDM (n-dodecyl-β-D-
maltoside), DM (n-decyl-β-D-maltoside), OG (n-octyl-β-D-
glucoside), LMNG (2,2-Didecylpropane-1,3-bis-β-D-mal-
toside) and CHAPSO, the non-ionic detergent DDM
appeared to be most effective in terms of solubilizing
recombinant hENT1. The hENT1 protein was puriﬁed from
the membrane fractions by nickel afﬁnity chromatography
and further fractionated by gel ﬁltration. The puriﬁed hENT1
exhibited excellent solution behavior (Fig. 1B) and could be
easily visualized on SDS-PAGE by coomassie blue staining
(Fig. 1C). The peak fractions from gel ﬁltration contain two
co-migrating bands on the SDS-PAGE gel (Fig. 1C). Sam-
ples from both bands were conﬁrmed to be hENT1 by mass
spectrometry. hENT1 has a molecular weight of approxi-
mately 50.2-kDa, which is consistent with that of the lower
band on the gel (Fig. 1C). The higher molecular weight band
may correspond to the oligomeric form of hENT1. The
analysis is supported by a recent report that hENT1
expressed in Sf9 insect cells contained an oligomeric form
(Rehan and Jaakola, 2015).
Transport activity of hENT1
All reported studies aimed at characterizing the ENTs
transport mechanism relied exclusively on assays that were
performed in native cell membranes (Ward et al., 2000;
SenGupta and Unadkat, 2004; Endres and Unadkat, 2005;
Visser et al., 2007; Paproski et al., 2008; Aseervatham et al.,
2015). No homogeneous mammal ENTs protein has been
used in any in vitro reconstituted assay. In the present
investigation, we reconstituted the homogeneous, recombi-
nant hENT1 protein into liposomes and established a pro-
teoliposomes-based counter ﬂow assay for the detection of
substrate transport (Fig. 2A). In this assay, the tritium (3H)-
labeled substrate adenosine was present in the outside
buffer and its uptake into the liposomes was monitored
(Fig. 2A). Compared to the protein-free liposomes or the
liposomes with incorporation of a control membrane trans-
porter GLUT3 (Deng et al., 2015), only hENT1-incorporated
liposomes supported the uptake of 3H-adenosine (Fig. S1A).
A time course analysis of substrate uptake showed that
adenosine was most rapidly transported into the liposomes
within the initial 10 s and the accumulated amount of ade-
nosine in the liposomes remained largely unchanged
between 10 and 30 s (Fig. 2B). Due to the nature of the
counter ﬂow assay and the much higher concentrations of
the unlabeled adenosine in the liposomes, the amount of 3H-
adenosine in the liposomes gradually declined after 30 s
(Fig. 2B). Nonetheless, the 30-second time point is more
amenable to manipulation and allows acquisition of more
accurate data. Therefore, except for the determination of
Vmax, we used the 30-second time point for the qualitative
characterization of hENT1. First, we investigated the pH
dependence of hENT1 transport activity. The accumulated
amount of 3H-adenosine in the liposomes remained largely
pH-independent from pH 4.5 to 8.5 (Fig. 2C). This analysis
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suggests no critical role by Asp, Glu, or His residues in the
transport mechanism of hENT1.
Next, we sought to determine the Km and Vmax of hENT1
transport at pH 6.5. Using varying concentrations of unla-
beled adenosine and a constant concentration of 3H-ade-
nosine outside the liposomes, we measured the amount of
accumulated 3H-adenosine in the liposome at the 10-second
time point. The transport rates were plotted against the
concentrations of the substrate (unlabeled adenosine); the
plot conformed to simple Michaelis-Menten kinetics and
allowed determination of the Km and Vmax values (Fig. 2D).
The calculated Km value of 215 ± 34 µmol/L for the puriﬁed
hENT1 is about half of that derived from hENT1 expressed in
Xenopus oocytes (Aseervatham et al., 2015) (Fig. S1B), but
5-10 folds higher than those from hENT1 expressed in yeast
and PK15 cell (Ward et al., 2000; Yao et al., 2001; Visser
et al., 2005; Paproski et al., 2008) (Fig. S1B). Such differ-
ences can be attributed to a range of factors, including but
not limiting to differences in lipid environment, surrounding
protein factors, and quantiﬁcation methods.
The inhibitors of ENTs modulate a variety of physiological
processes by changing the extracellular adenosine con-
centrations and ENT inhibitors have a well-established role
in the treatment of many diseases including cancer, HIV, and
cardiovascular diseases (King et al., 2006; Jordheim et al.,
2013). For example, the cytotoxic effect of the chemothera-
peutic agent cladribine to the cultured acute lymphocytic













































Figure 1. Expression and puriﬁcation of hENT1 in HEK293F cells. (A) The predicted topology diagram of hENT1. hENT1 has 11
transmembrane segments, with a cytoplasmic amino-terminus and an extracellular carboxyl-terminus. The positions of the
glycosylation site and two long loops are indicated. (B) A representative chromatogram of hENT1 from gel ﬁltration chromatography.
The elution volume of hENT1 in the Superdex-200 column gel ﬁltration is indicated. (C) Visualization of hENT1 on a SDS-PAGE gel.
The peak fractions from gel ﬁltration were applied onto a SDS-PAGE gel followed by coomassie blue staining.
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nitrobenzylmercaptopurine ribonucleoside (NBMPR) (Wright
et al., 2000). Consistent with its therapeutic activity, NBMPR
displays an inhibitory constant (IC50) of approximately 141
nM for hENT1 in the in vitro counter ﬂow assay (Fig. S1C).
Speciﬁc binding of adenosine and adenine to hENT1
hENT1 and hENT2 are known to transport a broad range of
purine and pyrimidine nucleosides (Ward et al., 2000;
Baldwin et al., 2004; Boswell-Casteel and Hays, 2016;
Young, 2016) (Fig. 3A and Fig. S2). In contrast to hENT2 that
can efﬁciently transport nucleobases, hENT1 is thought to
have much reduced transport ability for nucleobases (Yao
et al., 2002; Yao et al., 2011). This functional property of
hENT1 is likely related to its ability to bind the nucleosides
versus the nucleobases. To assess this possibility, we used
isothermal titration calorimetry (ITC) to determine the ther-
modynamic parameters of hENT1-ligand interactions in
solution. In these experiments, concentrated substrates (5
mmol/L nucleosides or 10 mmol/L nucleobase) in the syringe
were injected into the cell, where hENT1 was present at 0.1
mmol/L. The calculated dissociation constant (Kd) between
hENT1 and adenosine is approximately 0.45 ± 0.03 mmol/L,
which is in good agreement with the calculated Km value as
determined in the proteoliposome-based counter ﬂow assay
(Fig. 2D and Fig. 3B). Intriguingly, hENT1 shows a slight
preference for deoxyadenosine over adenosine, with a Kd of
0.19 ± 0.04 mmol/L (Fig. 3C). In sharp contrast to adenosine
and deoxyadenosine, hENT1 binds the nucleobase adenine
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Figure 2. Transport activity of hENT1. (A) A schematic diagram of the counter ﬂow assay. Uptake of 3H-labeled adenosine into the
hENT1-incorporated liposome was monitored. (B) A time course analysis of the transport activity of hENT1. (C) The transport activity
of hENT1 is pH-independent as measured in the liposome-based counter ﬂow assay. P values between different pH values and pH
4.5 are indicated. Control (pH 4.5) refers to the condition where protein-free liposomes were used. (D) Determination of Km and Vmax
for the transport of adenosine by hENT1. hENT1 proteoliposome was incubated in the presence of increasing concentrations of
unlabeled adenosine. The Km value was determined by non-linear regression analysis using GraphPad Prism version 5.0 software.
Each data point represents the average of at least three independent experiments. The error bars represent standard deviation (SD).
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L (Fig. 3D). This ﬁnding suggests that the ribose moiety may
be directly recognized by amino acids from hENT1.
The interactions between the nucleosides/nucleobases
and hENT1 are highly speciﬁc. In the ITC assays, the puri-
ﬁed hENT1 protein exhibited no detectable binding to the
nucleoside guanosine, 5-methyuridine, uridine, or cytidine
(Fig. S3A). hENT1 also failed to interact with the deoxynu-
cleoside deoxyguanosine, thymidine, deoxyuridine, or
deoxycytidine (Fig. S3B). Finally, hENT1 displayed no
binding to the nucleobase guanine, thymine, uracil, or cyto-
sine (Fig. S3C). Guanosine or deoxyguanosine has the
same ribose (deoxyribose) backbone with adenosine or
deoxyadenosine; but hENT1 exhibited no detectable binding
to guanosine or deoxyguanosine in the ITC assays. These
results suggest that the adenine base is speciﬁcally
recognized by amino acids from hENT1. Taken together, our
data demonstrate that hENT1 only speciﬁcally bind adeno-
sine, deoxyadenosine, and to a lesser extent adenine while
exhibiting no apparent binding to other nucleosides,
deoxynucleosides, or nucleobases. These results indicate
that both nucleobase and ribose/deoxyribose are involved in
interactions with hENT1.
Transport of nucleosides and nucleoside-derived drugs
by hENT1
All four hENT members can transport adenosine, but are
distinguished functionally by their different transport capa-
bilities for other nucleosides and nucleobases (Ward et al.,
2000; Yao et al., 2002; Barnes et al., 2006; Govindarajan
Adenine
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Figure 3. Determination of binding afﬁnities between hENT1 and adenosine, deoxyadenosine, or adenine. (A) Chemical
structures of adenosine, deoxyadenosine, and adenine. (B) Measurement of the binding afﬁnity between hENT1 and adenosine by
ITC. Curve ﬁtting revealed a dissociation constant of 0.45 ± 0.03 mmol/L. The curve was ﬁtted by Origin 7. (C) Measurement of the
binding afﬁnity between hENT1 and deoxyadenosine by ITC. (D) Measurement of the binding afﬁnity between hENT1 and adenine by
ITC.
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et al., 2009; Yao et al., 2011). We reconstituted a liposome-
based competition assay to examine substrate selectivity by
hENT1 (Fig. 4A). In this assay, concentrations of the unla-
beled adenosine in the liposomes and 3H-adenosine in the
buffer were kept constant, and 500 µmol/L nucleoside or
nucleobase was added to the buffer. The transport activity of
hENT1 for 3H-adenosine was more than 90 percent reduced
by the presence of unlabeled adenosine, 5-methyluridine,
uridine, deoxyadenosine, deoxyguanosine, thymidine, and
deoxyuridine (Fig. 4B). Unlabeled guanosine, cytidine, and
deoxycytidine also markedly decreased the transport of 3H-
adenosine by hENT1 (Fig. 4B). In contrast, the nucleobases
adenine, guanine, thymine, uracil, and cytosine were less
efﬁcient in the competition assay (Fig. 4B). Because these
nucleosides and nucleobases exhibit no detectable binding
to hENT1, they likely competed with 3H-adenosine for
transport by hENT1, rather than for binding by hENT1.
These results are consistent with previous conclusion that
hENT1 robustly transports nucleosides and to a lesser
extent nucleobases (Yao et al., 2011).
Nucleoside-derived and nucleobase-derived drugs are
used in antiviral and anticancer therapies, and their inter-
actions with ENTs have been extensively discussed (Bald-
win et al., 2004; Jordheim and Dumontet, 2007; Jordheim
et al., 2013; Young et al., 2013; Nordh et al., 2014; Catala
et al., 2016). For example, capecitabine, clofarabine, and
5-ﬂuorouracil have efﬁcacy on a variety of solid tumors, and
ribavirin and acyclovir are used to treat several forms of viral
infection (Jordheim et al., 2013; Young et al., 2013) (Fig. 5A).
In all cases, an essential step during treatment is for the drug
to be efﬁciently imported into the cells. Presumably these
nucleoside- and nucleobase-derived drugs are transported
by ENTs. To investigate this scenario, we performed a similar
liposome-based competition assay (Fig. 5B). Somewhat
surprisingly, none of these drugs was able to compete as
efﬁciently as adenosine. The nucleobase-derived drugs
acyclovir and 5-ﬂuorouracil failed completely to compete
(Fig. 5B). These results strongly argue that, if hENT1 were
the primary target for any of these drugs as widely suspected
in the clinic, more potent drugs should be uncovered through
chemical modiﬁcation of existing ones. Presumably, drugs
that retains high-afﬁnity binding to hENT1 but cannot be
transported by hENT1 may represent the best possible drug
candidate. Most notably, elevated hENT1 expression is
regarded as a therapeutic biomarker for pancreatic adeno-
carcinoma and breast cancer in the clinic (Nordh et al., 2014;
Pastor-Anglada and Perez-Torras, 2015).
Impact of hENT1 mutation on transport
hENT1 and hENT2 exhibit high sequence identity (Fig. 6A).











































































































Figure 4. Substrate speciﬁcity of hENT1. (A) A schematic diagram of the competition assay. The proteoliposomes were preloaded
with 20 mmol/L unlabeled adenosine, then diluted into 100 μL assay buffer containing 0.22 μmol/L 3H-adenosine and 500 μmol/L
competitor - one of the listed nucleosides and nucleobases in panel B. (B) Transport activity for nucleosides, deoxynucleosides, and
nucleobases. The transport of 3H-adenosine by recombinant hENT1 protein was examined in the proteoliposome-based counter ﬂow
assays in the presence of the indicated nucleosides, deoxynucleosides, and nucleobases. Control refers to the condition where no
other substrate was added. No protein refers to the condition where protein-free liposomes were used. The black boxes represent the
transport activity of nucleoside and deoxynucleoside for hENT1, whereas the green boxes represent the transport activity for
nucleobase. Each data point represents the average of at least three independent experiments. The error bars represent standard
deviation (SD).
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Figure 5. Nucleoside-derived drugs inhibit the transport activity of hENT1. (A) Chemical structures of representative
nucleoside-derived and nucleobase-derived drugs. The drugs were used to treat cancer and virus infection in the clinic. (B) Transport
activity of hENT1 for nucleoside-derived and nucleobase-derived drugs. No competitor refers to the condition where no other
substrate was added. No protein refers to the condition where protein-free liposomes were used. The black boxes represent the
transport activity of nucleoside-derived drugs for hENT1, whereas the orange boxes represent the transport activity for nucleobase-
derived drugs. Each data point represents the average of at least three independent experiments. The error bars represent standard
deviation (SD).
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amino acids and individually puriﬁed the six hENT1 variants
to homogeneity for the detection of their transport activity.
Met33 of hENT1 was previously shown to be responsible for
sensitivity to inhibitors such as dilazep and dipyridamole, but
not NBMPR (Visser et al., 2002). In our assay, the mutation
M33I had no effect on the transport activity of hENT1
(Fig. 6B). Gly179 of hENT1 was thought to be crucial for
nucleoside transport and sensitive to inhibition by NBMPR
(SenGupta et al., 2002). Consistent with the published data,
the mutation of Gly179 to Leu (G179L) led to 90 percent
reduction of the transport activity for adenosine (Fig. 6B).
Four additional mutations, each involving a conserved
hydrophobic residue, had different impacts on the transport
activity of hENT1. No signiﬁcant difference (P = 0.2469) was
detected in the ability of adenosine transport for F390A
(Fig. 6B). While compared to WT protein, mutations F209A
(P < 0.01), P308A (P < 0.001), and L442I (P < 0.001)




























































































































Figure 6. Effect of mutations on the transport activity of hENT1. (A) Sequence alignment among hENT1, three ENT1 orthologs
from other species, hENT2, and two ENT2 orthologs from other species. Homo ENT1: Homo sapiens, GI: 118582262; Macaca ENT1:
Macaca mulatta, GI: 383872534; Oryctolagus ENT1: Oryctolagus cuniculus, GI: 655841520; Mus ENT1: Mus musculus, GI:
312283707; Homo ENT2: Homo sapiens, GI: 38708299; Mus ENT2: Mus musculus, GI: 194248086; Xenolus ENT2: Xenopus
tropicalis, GI: 62859387. Conserved residues are highlighted in gray. Six representative residues in panel B are indicated by red
asterisks. (B) Transport activity of hENT1 variants. Six variants of hENT1 were generated and the proteins were individually puriﬁed to
homogenous for transport assay. Control refers to the condition where protein-free liposomes were used. Each data point represents
the average of at least three independent experiments. The error bars represent standard deviation (SD).
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(Fig. 6B). These results suggest that Phe209, Pro308 and
Leu442 may have direct or indirect interactions with
adenosine.
To verify the effect of these mutations on the transport
activity of hENT1, a structural model for hENT1 was gener-
ated (Fig. S4). Among the mutated residues, Met33, Gly179,
Pro308, and Leu442 are located in the putative transport
path of hENT1 (Fig. S4), suggesting potential involvement in
the substrate transport. Consistent with this observation,
G179L, P308A, and L442I led to a signiﬁcant decrease in
adenosine transport (Fig. 6B). Met33 is responsible for the
sensitivity to inhibitors (Visser et al., 2002), but not for the
substrate transport (Fig. 6B). Phe209 is positioned on TM6
and F209A probably lead to the impairment of conforma-
tional ﬂexibility required for transport activity (Fig. 6B and
Fig. S4). Phe390 is far away from the transport path
(Fig. S4), which is consistent with the functional assay in
which F390A has no effect on the transport activity (Fig. 6B).
DISCUSSION
Despite growing interests in hENTs (Aseervatham et al.,
2015; Rehan et al., 2015; Rehan and Jaakola, 2015), many
of their biochemical properties such as substrate binding and
transport mechanism are poorly understood. Biochemical
characterization of hENTs has been limited by the inability to
obtain recombinant protein with transport activity. Conse-
quently, functional analysis of these transporters has been
performed in native membranes (Ward et al., 2000; Sen-
Gupta and Unadkat, 2004; Endres and Unadkat, 2005;
Visser et al., 2007; Paproski et al., 2008; Aseervatham et al.,
2015; Rehan et al., 2015; Rehan and Jaakola, 2015), which
is affected by other nucleoside transporters such as CNTs
and multidrug resistance transporters. To date, only a puta-
tive ENT homologue FUN26 from S. cerevisiae was puriﬁed
to homogeneity and incorporated into proteoliposome (Bos-
well-Casteel et al., 2014). In this study, we report the suc-
cessful expression of hENT1 in human HEK293F cells. The
recombinant protein was puriﬁed to homogeneity and sub-
jected to functional characterization in the liposome-based
counter ﬂow assay and isothermal titration calorimetry. To
our knowledge, such effort represents the ﬁrst of its kind for
any mammalian ENT transporter.
Although hENT1 binds to adenosine and deox-
yadenosine, it fails to interact with other nucleosides or
deoxynucleosides (Fig. S3). This result is a bit surprising,
suggesting high speciﬁcity for the adenine base. Despite the
binding preferences, adenosine transport by hENT1 is
competitively inhibited by these nucleosides and deoxynu-
cleosides (Fig. 4B). Previous studies showed that these
nucleosides and deoxynucleosides could be transported by
hENT1 (Vickers et al., 1999; Ward et al., 2000; Yao et al.,
2002; Baldwin et al., 2004; Young et al., 2013). Thus, these
nucleosides and deoxynucleosides competed with adeno-
sine for transport by hENT1, hence reducing its activity for
adenosine.
The inhibitor NBMPR exhibited an IC50 of about 141 nM
for the transport activity of hENT1 (Fig. S1C). Given the
similarity in their chemical structures, we suspected that
NBMPR directly competed with adenosine for binding to
hENT1. Surprisingly, however, no detectable binding was
observed between NBMPR and hENT1 by ITC (data not
shown). This result strongly argues that NBMPR, similar to
other nucleosides, may simply compete with adenosine for
transport by hENT1.
Taken together, we report successful puriﬁcation and
biochemical characterization of hENT1 in vitro functional
assay. Results reported in this manuscript represent improve
our understanding on the transport properties of hENT1.
Obviously, such biochemical data should be ideally recon-
ciled by structural information, which is ostensibly absent for
any mammalian ENT member. Nonetheless, puriﬁcation of
hENT1 in a functional form constitutes a major step towards
its eventual crystallization and structure determination.
MATERIALS AND METHODS
Protein preparation
The cDNA of wild-type (WT) human ENT1 (hENT1) with a single
N48Q mutation was cloned into the pCAG vector. Endo-free plasmid
pre-mixed with linear polyethylenimines (PEIs) (Polysciences) (1:3,
w/w) was transfected into HEK293F cells (Invitrogen) when the
density reached 2 × 106 cells/mL. For each experiment, approxi-
mately 1 mg plasmids were pre-mixed with 3 mg PEIs in 50 mL fresh
SMM 293T-I medium (Sino Biological Inc.) for 15–30 min before
transfection. For transfection, the 50 mL mixture was added to one
Liter cell culture and incubated for 30 min. Cells were cultured in the
incubator shaker (INFORS HT, Multitron Pro) at 37°C. After growth
for 72 h, the transfected cells were harvested, resuspended in lysis
buffer containing 25 mmol/L Tris-HCl, pH 8.0, 150 mmol/L NaCl, and
protease inhibitor cocktails (Amresco), and disrupted by sonication
on ice. Cell membrane was collected by ultracentrifugation at
150,000 g for 1 h. The membrane pellet was resuspended in the
lysis buffer and incubated for 1.5 h with 2.0% (w/v) dodecyl-β-D-
maltopyranoside (DDM, Anatrace) at 4°C. After another ultracen-
trifugation step at 150,000 g for 30 min, the supernatant was loaded
onto Ni2+-nitrilotriacetate afﬁnity resin (Ni-NTA; Qiagen), incubated
at 4°C for 15 min and washed with buffer containing 25 mmol/L Tris-
HCl, pH 8.0, 150 mmol/L NaCl, 30 mmol/L imidazole, and 0.02%
DDM. The target protein was eluted from the afﬁnity resin with buffer
containing 25 mmol/L Tris-HCl, pH 8.0, 150 mmol/L NaCl, 250 mmol/
L imidazole, and 0.02% DDM. The eluted solution was concentrated
to about 5 mg/mL before further puriﬁcation by gel ﬁltration (Su-
perdex-200, GE Healthcare) in buffer containing 0.02% DDM, 30
mmol/L HEPES, pH 7.4, and 150 mmol/L NaCl. The peak fractions
were collected, ﬂash-frozen in liquid nitrogen and stored at −80°C for
later use.
Preparation of liposomes and proteoliposomes
50 mg/mL E.coli polar lipids (Avanti Polar Lipids, Inc.) were dis-
solved in chloroform and methanol mixture (3:1, v/v), the organic
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solvent was removed by nitrogen stream. The remained lipid layer
was resuspended to 20 mg/mL in assay buffer containing 40 mmol/L
MES, pH 6.5, 40 mmol/L KCl, and 2 mmol/L MgSO4. After fast frozen
and thawed for 10 cycles, the mixture was extruded through 0.4 μm
membrane ﬁlter (Whatman). 1% n-octyl-β-D-glucoside (β-OG, Ana-
trace), 20 mmol/L adenosine, and the protein hENT1 or GLUT3 (a
glucose transporter) was then added into the mixture (protein: lipid =
1:100, w/w). For blank control, equal volume of the same buffer used
in the ﬁnal step of protein puriﬁcation was added. After incubation at
4°C for 1 h, β-OG was removed by incubation with 320 mg/mL Bio-
Beads SM2 (Bio-Rad) overnight. After separation from detergent-
absorbed beads, the mixture was repeatedly frozen and thawed for
ﬁve cycles. The proteoliposomes were extruded through 0.4 μm
membrane ﬁlter again and collected by an ultracentrifugation step at
100,000 g for 1 h. The collected proteoliposomes were washed twice
with the cold assay buffer. The proteoliposomes were on ice and
resuspended in cold assay buffer before use with a ﬁnal concen-
tration of 100 mg/mL.
Liposome-based counter ﬂow assay
All counter ﬂow assays were performed at room temperature. For each
assay, 2 μL of prepared proteoliposomes as described above was
added into 98 μL of the assay buffer containing 0.5 μL of 3H-adenosine
(23 Ci mmol−1, Moravek Chemicals) to start reaction. The ﬁnal con-
centration of external 3H-adenosine was 0.22 μmol/L. Each reaction
lasted 30 s, if not otherwise indicated, and was stopped by rapidly
ﬁltering the reaction solution through a 0.22-μmGSTF ﬁlter (Millipore).
The ﬁlter membrane was washed with 2 mL assay buffer and solubi-
lized with Optiphase HISAFE 3 (PerkinElmer), used for liquid scintil-
lation counting. All experiments were repeated at least three times.
Isothermal titration calorimetry
MicroCal iTC200 (GE Healthcare) was used to measure the binding
afﬁnities between hENT1 and substrates at 22°C. The hENT1 protein
was prepared in a buffer containing 0.02% DDM, 30 mmol/L HEPES
pH 7.4, and 150 mmol/L NaCl. Substrates were prepared in the same
buffer, except that 1%DMSOor ethanol was used to help dissolve the
substrates. During a titration experiment, the hENT1 protein concen-
tration was 0.1 mmol/L in the cell, while substrates in the syringe were
5 mmol/L for nucleosides or deoxynucleosides, and 10 mmol/L for
nucleobases. Data was ﬁtted by software Origin 7.0 (MicroCal).
Structural modelling of human ENT1 (hENT1)
A hENT1 structure model was constructed using RaptorX web ser-
ver (Wang and Xu, 2013; Ma et al., 2015; Wang et al., 2016) based
on contact map prediction. 1610 sequence homologs were used for
multi-sequence alignment (MSA). The contact information extracting
from MSA was considered on high conﬁdence level for conserved
regions. The hENT1 model appears to contain eleven transmem-
brane segments in general as reported.
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